Glaukos Co. (NYSE:GKOS – Get Rating) has received an average recommendation of “Hold” from the eleven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $56.67.
Several brokerages recently commented on GKOS. Mizuho began coverage on shares of Glaukos in a research note on Thursday, December 22nd. They set a “neutral” rating and a $48.00 price target on the stock. JPMorgan Chase & Co. upgraded shares of Glaukos from an “underweight” rating to a “neutral” rating and cut their price target for the stock from $48.00 to $42.00 in a research note on Monday, December 19th. StockNews.com lowered shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday. Wells Fargo & Company dropped their price objective on shares of Glaukos from $56.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Monday, December 12th. Finally, Needham & Company LLC dropped their price objective on shares of Glaukos from $66.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, November 3rd.
Institutional Trading of Glaukos
Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Glaukos by 0.4% during the third quarter. Vanguard Group Inc. now owns 5,380,720 shares of the medical instruments supplier’s stock worth $286,470,000 after buying an additional 23,473 shares in the last quarter. State Street Corp boosted its holdings in Glaukos by 1.0% during the second quarter. State Street Corp now owns 1,698,257 shares of the medical instruments supplier’s stock worth $77,135,000 after buying an additional 16,315 shares in the last quarter. Fred Alger Management LLC boosted its holdings in Glaukos by 34.3% during the third quarter. Fred Alger Management LLC now owns 1,402,110 shares of the medical instruments supplier’s stock worth $74,648,000 after buying an additional 358,360 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in Glaukos by 13.8% during the second quarter. Point72 Asset Management L.P. now owns 1,321,902 shares of the medical instruments supplier’s stock worth $60,041,000 after buying an additional 160,347 shares in the last quarter. Finally, Lord Abbett & CO. LLC purchased a new stake in Glaukos during the third quarter worth about $61,056,000. Hedge funds and other institutional investors own 92.17% of the company’s stock.
Glaukos Price Performance
Glaukos (NYSE:GKOS – Get Rating) last announced its quarterly earnings data on Wednesday, November 2nd. The medical instruments supplier reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.08. Glaukos had a negative net margin of 31.45% and a negative return on equity of 16.16%. The business had revenue of $71.27 million for the quarter, compared to analyst estimates of $67.88 million. Equities analysts forecast that Glaukos will post -2.23 EPS for the current fiscal year.
Glaukos Company Profile
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.
- Get a free copy of the StockNews.com research report on Glaukos (GKOS)
- 3 Retail Stocks Ringing the Register in 2023
- When Will Crane Holdings Take Flight?
- Is It Time To Get Aggressive With Defense Stocks?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.